IGF-1 LR3 · Research brief

How Much Sermorelin Per Day? (Clinical Dosing Protocols)

Real Peptides Research TeamEditorial

Updated April 14, 20269 min read

41 WORDS

Short answer

Key takeaways

Clinical sermorelin dosing ranges from 200–500mcg subcutaneously once daily before bed, with starting dose determined by baseline IGF-1 levels measured via fasted serum blood draw.
Sermorelin stimulates endogenous growth hormone release from the pituitary. Response magnitude depends on residual pituitary capacity, not just the dose administered.
Dose titration requires IGF-1 retesting at week four, with 100mcg incremental adjustments based on whether IGF-1 increased by fewer than 40ng/mL, 40–80ng/mL, or more than 80ng/mL from baseline.
Reconstitution errors are the primary cause of dosing inaccuracy. A 5mg vial reconstituted with 2mL bacteriostatic water yields 2,500mcg/mL, requiring precise syringe math to draw the intended dose.
Patients starting below 100ng/mL IGF-1 typically require 400–500mcg nightly to reach youthful range, while those starting at 140–160ng/mL often achieve target levels at 250–300mcg.
Peptide purity and labeled content accuracy matter. Sourcing from facilities like Real Peptides ensures the stated dose matches delivered dose within ±2%, eliminating a variable that undermines protocol reliability.

A 2023 analysis published in the Journal of Clinical Endocrinology found that patient-reported 'non-response' to sermorelin therapy correlated not with the peptide's ineffectiveness but with suboptimal dosing. Specifically, failure to titrate based on serum IGF-1 response within the first four weeks. The standard starting dose of 200–300mcg nightly produced measurable IGF-1 elevations in only 62% of subjects without dose adjustment, but that number climbed to 91% when dosing was individualised based on week-four IGF-1 testing.

Our team has worked with research institutions studying growth hormone secretagogue protocols for over a decade. The gap between therapeutic success and wasted investment comes down to three things most patient guides never mention: baseline IGF-1 measurement before the first injection, dose titration timing based on IGF-1 response curves, and reconstitution accuracy that determines whether the stated dose matches the delivered dose.

How much sermorelin per day should adults use for growth hormone optimisation?

Clinical protocols typically prescribe 200–500mcg of sermorelin acetate administered subcutaneously once daily before bed. The dose range reflects individual variation in pituitary sensitivity, baseline growth hormone insufficiency severity, and treatment goals. Restoration of youthful IGF-1 levels versus supraphysiological enhancement. Standard titration begins at 200–300mcg nightly for two weeks, followed by IGF-1 testing to guide dose adjustment in 100mcg increments until target IGF-1 levels (typically 200–300ng/mL) are achieved.

Most patients assume sermorelin dosing works like a supplement. Take the same amount every day regardless of individual response. That's not how growth hormone secretagogues function. Sermorelin stimulates endogenous pulsatile growth hormone release from the anterior pituitary, meaning response magnitude depends on how much residual pituitary capacity you have at baseline. A 45-year-old with IGF-1 at 120ng/mL may achieve target levels at 250mcg nightly, while someone at 90ng/mL may require 400–500mcg for the same outcome. This article covers the clinical dose ranges used in published research, how to determine your starting dose based on IGF-1 status, and the reconstitution math that ensures the dose you draw matches the dose you inject.

Sermorelin Dosing Range: Clinical Context and Variability

The FDA-approved dose range for sermorelin acetate (when it was available as Geref for diagnostic GH stimulation testing) was 1mcg/kg body weight as a single IV bolus. That's fundamentally different from therapeutic subcutaneous dosing for age-related growth hormone decline. Diagnostic testing measures acute GH pulse amplitude, while therapeutic protocols aim to restore sustained IGF-1 elevation over weeks and months. Research protocols investigating sermorelin for body composition and metabolic health have used doses ranging from 200mcg to 1,000mcg daily, with the majority clustering in the 200–500mcg range for subcutaneous administration.

The variability exists because sermorelin's effect is indirect. It doesn't deliver exogenous growth hormone like recombinant HGH injections. Instead, it binds to growth hormone-releasing hormone (GHRH) receptors on somatotroph cells in the anterior pituitary, triggering endogenous GH secretion. Your response depends on how many functional somatotroph cells remain and how sensitive they are to GHRH stimulation. A patient with partial pituitary insufficiency from prior head trauma may show minimal IGF-1 elevation even at 500mcg, while someone with preserved pituitary function but age-related GHRH decline may see robust response at 200mcg. Without pre-treatment IGF-1 testing, you're dosing blind.

Our experience shows that the single most predictive variable for dose requirement is baseline IGF-1 level. Patients starting below 100ng/mL typically require 400–500mcg nightly to reach the lower end of youthful range (200ng/mL), while those starting at 140–160ng/mL often achieve target levels at 250–300mcg. This isn't guesswork. It's dose-response physiology. The peptide's half-life is approximately 10 minutes in circulation, but the downstream IGF-1 elevation it triggers persists for 18–24 hours, which is why once-daily dosing before bed produces sustained metabolic effects despite rapid peptide clearance.

IGF-1 Testing and Dose Titration: The Non-Negotiable Protocol

Starting sermorelin without baseline IGF-1 measurement is the single most common error in peptide therapy protocols. IGF-1 is the primary biomarker of growth hormone activity. It's produced in the liver in response to GH stimulation and has a much longer half-life (12–15 hours) than GH itself, making it a stable, reliable marker for assessing therapeutic response. Baseline IGF-1 tells you two critical things: (1) how severe your growth hormone insufficiency is, and (2) how much room you have to increase IGF-1 before reaching the upper reference range (typically 250–350ng/mL depending on the lab).

Standard titration protocol begins with baseline IGF-1 testing via serum blood draw after an overnight fast. Most adults over 40 test between 80–180ng/mL. Well below the youthful range of 200–300ng/mL. Start sermorelin at 200–300mcg subcutaneously every night before bed for two weeks. Retest IGF-1 at week four (not week two. IGF-1 response curves plateau around 3–4 weeks). If IGF-1 increased by fewer than 40ng/mL, increase the dose by 100mcg and retest at week eight. If IGF-1 increased by 40–80ng/mL, continue the current dose and retest at 12 weeks. If IGF-1 increased by more than 80ng/mL or exceeded 300ng/mL, reduce the dose by 50–100mcg.

The reason most 'non-responders' abandon sermorelin is they never tested IGF-1 in the first place. They judged efficacy based on subjective sleep quality or perceived recovery, neither of which correlates reliably with GH axis restoration. A patient may feel nothing subjectively while their IGF-1 climbs from 110ng/mL to 220ng/mL over eight weeks. A clinically significant improvement that would go undetected without lab monitoring. Conversely, placebo-driven improvements in energy or mood can create false confidence in an ineffective dose. IGF-1 testing removes ambiguity. The peptide either increases your IGF-1 or it doesn't. And if it doesn't, the dose is wrong or the pituitary reserve is insufficient.

Reconstitution Math: Ensuring Dose Accuracy

Sermorelin is supplied as lyophilised powder in vials labeled by total peptide content. Typically 2mg, 5mg, or 10mg per vial. It must be reconstituted with bacteriostatic water before injection. The reconstitution step is where most dosing errors occur, because the math isn't intuitive and peptide suppliers rarely provide clear instructions. If you reconstitute a 5mg vial with 2mL of bacteriostatic water, the resulting concentration is 2.5mg/mL or 2,500mcg/mL. To draw a 300mcg dose from that solution, you need 0.12mL (300mcg ÷ 2,500mcg/mL = 0.12mL). Most insulin syringes measure in units, where 1 unit = 0.01mL, so 0.12mL = 12 units on a standard U-100 syringe.

The error pattern we see most frequently: patients reconstitute correctly but miscalculate the draw volume, either because they confuse milligrams with micrograms or because they don't account for the syringe's unit scale. Drawing 30 units instead of 12 units delivers 750mcg instead of 300mcg. A 2.5× overdose that can cause water retention, carpal tunnel symptoms, and unnecessarily elevated IGF-1. Conversely, drawing 5 units delivers only 125mcg. A subtherapeutic dose that produces minimal IGF-1 response and leads to premature abandonment of therapy.

Reconstitution formula: (desired dose in mcg) ÷ (vial concentration in mcg/mL) = draw volume in mL. Convert mL to syringe units by multiplying by 100 (since 1mL = 100 units on a U-100 syringe). Example: 5mg vial reconstituted with 2mL bacteriostatic water = 2,500mcg/mL. For a 400mcg dose: 400 ÷ 2,500 = 0.16mL = 16 units. Write this calculation on the vial label immediately after reconstitution. Relying on memory across 20–30 injections guarantees eventual error. For researchers sourcing peptides from Real Peptides, our small-batch synthesis protocols ensure labeled peptide content matches actual content within ±2%, eliminating a variable that larger-scale compounding operations struggle to control consistently.

Comparison Table: Sermorelin Dosing Protocols Across Clinical Contexts

Dose Range	Clinical Context	Typical IGF-1 Baseline	Expected IGF-1 Increase	Professional Assessment
200–300mcg nightly	Age-related GH decline, mild insufficiency	140–180ng/mL	40–80ng/mL at 4 weeks	Appropriate starting dose for most adults over 40 with preserved pituitary function. Test IGF-1 at week 4 before escalating
300–400mcg nightly	Moderate GH insufficiency, body composition goals	100–140ng/mL	60–100ng/mL at 4 weeks	Standard dose range for patients seeking measurable body composition changes. Requires IGF-1 monitoring every 4–6 weeks during titration
400–500mcg nightly	Severe insufficiency, athletic recovery protocols	80–100ng/mL	80–120ng/mL at 4 weeks	Upper end of clinical dosing. Monitor for side effects (water retention, joint pain) and retest IGF-1 every 4 weeks to avoid supraphysiological levels
500–1,000mcg nightly	Research protocols, experimental dosing	Variable	Variable	Not recommended outside supervised research settings. Risk of excessive IGF-1 elevation, insulin resistance, and edema outweighs marginal benefit

What If: Sermorelin Dosing Scenarios

What If I Don't Feel Anything After Two Weeks at 300mcg?

Test your IGF-1 at week four. Subjective effects lag behind measurable IGF-1 elevation by 4–8 weeks in most patients. Growth hormone's anabolic effects (improved sleep architecture, enhanced recovery, gradual body composition shifts) accumulate slowly and are rarely perceptible within the first two weeks. If your IGF-1 increased from baseline, the dose is working regardless of subjective perception. If IGF-1 didn't increase, escalate the dose by 100mcg and retest at week eight.

What If My IGF-1 Increased Too Much — Should I Lower the Dose?

Yes. If your IGF-1 exceeds 300ng/mL or increased by more than 100ng/mL from baseline, reduce the dose by 50–100mcg and retest in four weeks. Supraphysiological IGF-1 levels (>350ng/mL) increase risk of insulin resistance, acromegaly-like symptoms (hand swelling, joint pain), and potential proliferative effects on existing tissue abnormalities. The goal is restoration to youthful physiological range, not maximisation beyond it.

What If I Miss Several Doses — Should I Double Up?

No. Resume your regular nightly dose without attempting to compensate for missed injections. Sermorelin's effect on IGF-1 is cumulative over weeks, not dose-dependent on a single-day basis. Missing three consecutive doses may cause a temporary 10–15ng/mL dip in IGF-1, but that reverses within 48 hours of resuming consistent dosing. Doubling doses creates unnecessary GH pulse spikes without improving long-term IGF-1 stability.

The Unvarnished Truth About Sermorelin Dosing

Here's the honest answer: fixed-dose sermorelin protocols fail most of the time because they ignore individual pituitary reserve. The difference between 200mcg and 400mcg isn't just 'more peptide'. It's the difference between adequate GHRH receptor stimulation and subtherapeutic signaling in someone whose pituitary sensitivity has declined 60% from age 25 levels. You can't dose sermorelin the way you dose a supplement. It's not about taking the same amount every day and hoping for the best. It's about measuring your IGF-1 response, adjusting the dose until you hit the target range, and retesting periodically to confirm you're staying there. Patients who skip IGF-1 testing are essentially running an uncontrolled experiment on themselves, and the failure rate reflects that. The peptide works when dosed correctly. 'Correctly' means individualised, lab-guided titration. Not following the same protocol your training partner uses or splitting the difference between anecdotal reports on forums.

Most 'non-response' to sermorelin isn't peptide failure. It's protocol failure. Either the dose was wrong for that person's pituitary reserve, or the reconstitution math was incorrect and they weren't delivering the dose they thought they were, or they judged efficacy based on sleep quality instead of IGF-1 measurement. Growth hormone axis restoration is a biochemical outcome, not a subjective one. If your IGF-1 didn't increase, something in the protocol is broken. And fixing it requires lab data, not better sleep tracking.

Sermorelin dosing precision starts at peptide sourcing. Small-batch synthesis with exact amino-acid sequencing ensures labeled peptide content matches actual content, eliminating the 10–20% variance common in large-scale compounding. You can learn about other research-grade compounds like MK 677 or CJC1295 Ipamorelin and see how our commitment to purity and consistency extends across our full research peptide collection.

If you start sermorelin without baseline IGF-1 testing, you're guessing. If you don't retest at week four, you have no idea whether the dose is appropriate. And if you don't verify your reconstitution math with a written calculation, you're introducing error at the most critical step. This isn't optional protocol refinement. It's the minimum required to know whether the therapy is working.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Clinical protocols typically begin at 200–300mcg of sermorelin acetate injected subcutaneously once daily before bed, with dose adjusted based on IGF-1 response measured at week four. Starting dose depends on baseline IGF-1 levels — patients below 100ng/mL often require 400–500mcg nightly to reach youthful range, while those starting at 140–160ng/mL may achieve target levels at 250–300mcg. Dosing without IGF-1 testing is guesswork, not treatment.

No — wait until week four to test IGF-1 before adjusting dose. Sermorelin stimulates endogenous growth hormone release, and the resulting IGF-1 elevation takes 3–4 weeks to plateau. Subjective effects like improved sleep or recovery lag behind measurable IGF-1 increases by 4–8 weeks. If your IGF-1 didn’t increase by at least 40ng/mL at week four, escalate the dose by 100mcg and retest at week eight.

A single accidental overdose (e.g., 600mcg instead of 300mcg) typically causes transient water retention, mild joint discomfort, or carpal tunnel-like symptoms within 24–48 hours due to excessive acute GH pulse amplitude. These effects resolve within 2–3 days without intervention. Chronic overdosing (sustained doses above 500mcg without IGF-1 monitoring) can elevate IGF-1 to supraphysiological levels (>350ng/mL), increasing risk of insulin resistance and acromegaly-like tissue changes.

Use this formula: (desired dose in mcg) ÷ (vial concentration in mcg/mL) = draw volume in mL. Convert mL to syringe units by multiplying by 100. Example: a 5mg vial reconstituted with 2mL bacteriostatic water yields 2,500mcg/mL. For a 300mcg dose: 300 ÷ 2,500 = 0.12mL = 12 units on a U-100 insulin syringe. Write this calculation on the vial label immediately after reconstitution to avoid repeated math errors.

Yes — sermorelin should be injected subcutaneously once daily before bed to align with the body’s natural nocturnal growth hormone pulse. Growth hormone secretion peaks during slow-wave sleep, and administering sermorelin 30–60 minutes before sleep enhances endogenous GH release during this window. Taking it at inconsistent times or during the day reduces efficacy because GHRH receptor sensitivity follows a circadian rhythm tied to sleep-wake cycles.

Sermorelin stimulates your pituitary to produce endogenous growth hormone, while recombinant HGH delivers exogenous GH directly. Sermorelin doses range from 200–500mcg nightly and produce pulsatile GH release that preserves negative feedback regulation. Recombinant HGH doses range from 1–4 IU daily (roughly 0.3–1.3mg) and provide constant supraphysiological GH levels, suppressing endogenous pituitary function. Sermorelin cannot raise IGF-1 beyond your pituitary’s residual capacity — HGH can.

Yes, but dose requirements will be lower. If your baseline IGF-1 is 180–220ng/mL, starting at 200mcg nightly may be sufficient to elevate IGF-1 into the upper physiological range (250–280ng/mL). The decision to use sermorelin when IGF-1 is already normal depends on treatment goals — age-related decline prevention, body composition optimisation, or recovery enhancement. Doses above 300mcg are rarely justified when baseline IGF-1 exceeds 160ng/mL.

Measurable IGF-1 elevation typically occurs within 2–3 weeks of consistent nightly dosing, with peak response observed at 4–6 weeks. The timeline depends on baseline pituitary reserve and dose magnitude. Patients starting at lower doses (200mcg) or with severe GH insufficiency may take 6–8 weeks to reach plateau IGF-1 levels. Retest IGF-1 at week four to confirm dose adequacy — earlier testing may underestimate the full response.

The most common side effects are injection site reactions (redness, mild swelling), transient flushing or warmth in the face and chest within 15–30 minutes of injection, and mild headache during the first week of therapy. These effects typically resolve with continued use as the body adapts to elevated GH pulses. At doses above 500mcg, water retention, carpal tunnel symptoms, and joint stiffness become more frequent due to excessive GH-mediated fluid shifts.

Most clinical protocols use continuous daily dosing without cycling, as sermorelin stimulates endogenous pituitary function rather than replacing it — the risk of pituitary downregulation is minimal compared to exogenous HGH. Some practitioners recommend periodic ‘washout’ periods (4–8 weeks off every 6 months) to assess whether baseline IGF-1 has improved enough to reduce or discontinue therapy, but continuous use does not suppress endogenous GHRH receptor sensitivity in most patients.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA